Advertisement


Howard M. Sandler, MD, on RTOG’s Past and NRG’s Future

2016 ASTRO Annual Meeting

Advertisement

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses prospective clinical trials as the gold standard of clinical decision-making and examines the infrastructure needed for future cancer research. (Abstract PS 3)



Related Videos

Prostate Cancer

Daniel Hamstra, MD, PhD, on Prostate Cancer: Decreasing Rectal Toxicity

Daniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality ...

Prostate Cancer

Paul L. Nguyen, MD, on Prostate Cancer: High-Risk Disease, Brachytherapy, And Hormones

Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he moderated, which included talks on local recurrence following brachytherapy, long-term PSA stability a...

Lung Cancer

Maria Werner-Wasik, MD, on Issues in Lung Toxicity

Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session she moderated on lung toxicity, including the impact of cardiac radiation, the risk of radiation ...

Head and Neck Cancer

Joanne B. Weidhaas, MD, PhD, on Head and Neck Cancer: Results of the NRG Oncology/RTOG 0522 Study

Joanne B. Weidhaas, MD, PhD, of the University of California, Los Angeles Radiation Oncology, discusses the KRAS variant as a biomarker of cetuximab response and altered immu...

Breast Cancer

Meena Moran, MD, on Ductal Carcinoma In Situ: Improving Local Control

Meena Moran, MD, of Yale University, discusses an analysis from 10 pooled academic institutions that showed a radiation boost after whole breast radiation therapy improves local contr...

Advertisement

Advertisement



Advertisement